Spots Global Cancer Trial Database for stem cell transplant
Every month we try and update this database with for stem cell transplant cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma | NCT01983969 | Advanced Cancer... Lymphoma | Azacitidine Vorinostat Gemcitabine Busulfan Melphalan Dexamethasone Caphosol Glutamine Pyridoxine Rituximab | 15 Years - 65 Years | M.D. Anderson Cancer Center | |
| A Study Evaluating a Proprietary Amino Acid Mixture (Enterade®) in Patients Receiving High-Dose Melphalan Conditioning Followed by Autologous Stem Cell Transplantation for Multiple Myeloma and Non-Hodgkin Lymphoma | NCT02919670 | Multiple Myelom... Non-Hodgkin's L... | Enterade Placebo Standard Suppor... | 18 Years - | Dana-Farber Cancer Institute | |
| High-dose Chemotherapy for Poor-Prognosis Relapsed Germ-Cell Tumors | NCT00936936 | Testicular Canc... | Gemcitabine Docetaxel Melphalan Carboplatin Mesna Ifosfamide Etoposide Stem Cell Trans... | 12 Years - 65 Years | M.D. Anderson Cancer Center | |
| Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 | NCT01044069 | Leukemia Acute Lymphobla... | gene-modified T... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders | NCT00636909 | AML ALL CML Chronic Pha... CLL MDS RELAPSED NON-HO... APLASTIC ANEMIA MULTIPLE MYELOM... MYELOPROLIFERAT... | Cyclophosphamid... fludarabine cyclosporine methotrexate G-CSF | - 65 Years | Beth Israel Deaconess Medical Center | |
| Peer i-Coaching for Activated Self-Management Optimization in Adolescents and Young Adults With Chronic Conditions | NCT03938324 | Sickle Cell Dis... Chronic Kidney ... Systemic Lupus ... Childhood Cance... Inflammatory Bo... Stem Cell Trans... Organ Transplan... Diabetes Mellit... Cystic Fibrosis | PiCASO Interven... Sham Comparator... | 16 Years - 22 Years | Duke University | |
| Allogeneic or Haploidentical Stem Cell Transplant Followed By High-Dose Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | NCT02057770 | Leukemia, Myelo... | busulfan fludarabine pho... total-body irra... Stem cell trans... cyclophosphamid... tocilizumab | 18 Years - | Washington University School of Medicine | |
| Use and Tolerability of Imatinib Mesylate (Gleevec) in Leukemia Patients | NCT00386373 | Leukemia | Imatinib Mesyla... | 16 Years - | M.D. Anderson Cancer Center | |
| Stem Cell Transplantation for Hematological Malignancies | NCT00176839 | Leukemia, Lymph... AML MDS | Stem Cell Trans... Busulfan Cyclophosphamid... Melphalan G-CSF ATG | - 35 Years | Masonic Cancer Center, University of Minnesota | |
| CD34+ Enriched Transplants to Treat Myelodysplastic Syndrome | NCT05617625 | Myelodysplastic... Graft Vs Host D... Graft-versus-ho... | Busulfan Melphalan Fludarabine CliniMACS CD34+... | 18 Years - 75 Years | Baptist Health South Florida | |
| Ex-Vivo Depletion of Myeloma Cells From Peripheral Blood Progenitor Cell Grafts | NCT00968396 | Multiple Myelom... | Apheresis Stem Cell Trans... Melphalan | 18 Years - 75 Years | M.D. Anderson Cancer Center | |
| Comprehensive Frailty Assessment | NCT02033928 | Myeloma, Multip... Paraproteinemia... Hematologic Neo... | 18 Years - | Ohio State University Comprehensive Cancer Center | ||
| Imatinib Mesylate, Busulfan, Fludarabine, and Antithymocyte Globulin for CML Patients | NCT00499889 | Leukemia | Imatinib Mesyla... Fludarabine (Fl... Busulfan Antithymocyte G... Tacrolimus Methotrexate Donor lymphocyt... Stem Cell Trans... | - 70 Years | M.D. Anderson Cancer Center | |
| The TOTOM Trial: Tai Chi to Optimize Transplant Outcomes for Multiple Myeloma | NCT04760405 | Multiple Myelom... Stem Cell Trans... | Tai Chi Easy | 18 Years - | University of Arizona | |
| Inpatient Palliative Care for Patients Undergoing Hematopoietic Stem Cell Transplantation | NCT03641378 | Stem Cell Trans... | Palliative Care... Standard Transp... | 18 Years - | Massachusetts General Hospital | |
| Administration of Rapidly Generated Multivirus-specific Cytotoxic T-Lymphocytes (VIRAGE) | NCT01070797 | Adenovirus Infe... Epstein-Barr Vi... Cytomegalovirus... Stem Cell Trans... | Multi-virus Spe... | - | Baylor College of Medicine | |
| FOB in HSCT and Leukemia Patients With Acute Respiratory Symptoms and Pulmonary Infiltrates | NCT01328873 | Pulmonary Infil... | Microbiological... | 18 Years - 80 Years | Northside Hospital, Inc. | |
| Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies | NCT02743351 | Hematologic Mal... Acute Myeloid L... Acute Lymphobla... Myelodysplastic... Chronic Myeloge... Acute Graft-ver... | ProTmune Control Arm | 18 Years - | Fate Therapeutics | |
| Phase II Study of Azacitidine and Sargramostim as Maintenance Treatment for Poor-Risk AML or MDS | NCT01700673 | Acute Myeloid L... Myelodysplastic... | Azacitidine Sargramostim | 6 Months - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Stem Cell Transplantation for Hematological Malignancies | NCT00176839 | Leukemia, Lymph... AML MDS | Stem Cell Trans... Busulfan Cyclophosphamid... Melphalan G-CSF ATG | - 35 Years | Masonic Cancer Center, University of Minnesota | |
| A Controlled Study of Stem Cell Transplantation Medical Home Care Compared to Standard Hospital Care | NCT01725022 | Hematologic Mal... | Home Care | 18 Years - 80 Years | Duke University | |
| The TOTOM Trial: Tai Chi to Optimize Transplant Outcomes for Multiple Myeloma | NCT04760405 | Multiple Myelom... Stem Cell Trans... | Tai Chi Easy | 18 Years - | University of Arizona | |
| Bevacizumab Plus Gemcitabine, Docetaxel, Melphalan, and Carboplatin in Ovarian Cancer Patients | NCT00583622 | Ovarian Cancer | Bevacizumab Carboplatin Docetaxel Gemcitabine Melphalan Stem Cell Trans... | 18 Years - 70 Years | M.D. Anderson Cancer Center | |
| Autologous Transplantation for Chronic Myelogenous Leukemia | NCT01003054 | Chronic Myeloge... | Busulfan Cyclophosphamid... Imatinib Mesyla... Autologous Stem... | - 70 Years | M.D. Anderson Cancer Center | |
| Busulfan Plus Clofarabine Followed by Allogeneic Hematopoietic Stem Cell Transplantation | NCT00990249 | Leukemia Lymphoma Allogeneic Haem... Acute Lymphobla... | Busulfan Clofarabine Thymoglobulin Stem Cell Trans... | - 65 Years | M.D. Anderson Cancer Center | |
| CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies | NCT00968760 | Lymphoma B-cell Lymphoma | Leukapheresis Stem Cell Trans... CD19-specific T... IL-2 Carmustine Etoposide Cytarabine Melphalan | 18 Years - 75 Years | M.D. Anderson Cancer Center | |
| Blood Stem Cell Transplantation for the Treatment of Older Patients With Acute Myelogenous Leukemia | NCT00623935 | Acute Myelogeno... | Fludarabine Busulfan Total Body Irra... Stem Cell Trans... | 55 Years - 70 Years | University of Michigan Rogel Cancer Center | |
| Stem Cell Transplantation for Hematological Malignancies | NCT00176839 | Leukemia, Lymph... AML MDS | Stem Cell Trans... Busulfan Cyclophosphamid... Melphalan G-CSF ATG | - 35 Years | Masonic Cancer Center, University of Minnesota | |
| Conditioning Regimen in Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation | NCT00429026 | Renal Cell Canc... | Fludarabine Melphalan Cyclophosphamid... Stem Cell Trans... | - 65 Years | M.D. Anderson Cancer Center | |
| A Randomized Trial to Compare Busulfan + Melphalan 140 mg/m2 With Melphalan 200 mg/m2 as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma | NCT01413178 | Myeloma | Busulfan Melphalan Questionnaire G-CSF High Dose Melph... Stem cell trans... | 18 Years - 70 Years | M.D. Anderson Cancer Center | |
| CD34+ Transplants for Leukemia and Lymphoma | NCT05565105 | Leukemia, Myelo... Leukemia, Lymph... | Total Body Irra... Thiotepa Cyclophosphamid... Busulfan Melphalan Fludarabine | 18 Years - 74 Years | Baptist Health South Florida | |
| Patient Reported Outcomes and Patient Education in Cellular Therapy Patients | NCT04853277 | Stem Cell Trans... CAR T-Cell Tran... CAR T-Cell Ther... Cellular Therap... Hematopoietic S... HSCT Multiple Myelom... Leukemia Lymphoma | Education | 18 Years - | Dartmouth-Hitchcock Medical Center | |
| CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma | NCT01746173 | T-cell Non-Hodg... | Cyclophosphamid... Doxorubicin Vincristine Etoposide Prednisone Filgrastim Plerixafor Stem Cell Colle... Palifermin Gemcitabine Busulfan Melphalan Stem Cell Trans... | 18 Years - 70 Years | Dana-Farber Cancer Institute | |
| Evaluate Rituximab in Obtaining PCR (Polymerase Chain Reaction) Negative Leukapheresis Product in Patients With Relapsed Follicular Lymphoma | NCT00856245 | Non-Hodgkins Ly... | Rituximab | 18 Years - | University of Kansas Medical Center | |
| CD34+ Enriched Transplants to Treat Myelodysplastic Syndrome | NCT05617625 | Myelodysplastic... Graft Vs Host D... Graft-versus-ho... | Busulfan Melphalan Fludarabine CliniMACS CD34+... | 18 Years - 75 Years | Baptist Health South Florida | |
| Intensive Chemo-Radiotherapy With Peripheral Blood Progenitor Cell Rescue for Children With Advanced Neuroblastoma and Sarcomas | NCT00165139 | Neuroblastoma Ewings Sarcoma Non-rhabdomyosa... | Vincristine Cyclophosphamid... Adriamycin Etoposide (VP-1... Cisplatin Carboplatin Melphalan Ifosfamide G-CSF (granuloc... Mesna | - 19 Years | Dana-Farber Cancer Institute | |
| Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in Myeloma | NCT02114502 | Myeloma | Carfilzomib SAHA Gemcitabine Busulfan Melphalan Stem Cell Trans... Palifermin Dexamethasone Caphosol Glutamine Pyridoxine | 18 Years - 65 Years | M.D. Anderson Cancer Center | |
| Dose Augmented Rituximab and ICE for Pts With Primary Refractory and Poor Risk Relapsed Aggressive B-Cell NHL | NCT00588094 | Lymphoma B-cell Non-Hodg... | Rituximab, Ifos... | 18 Years - 72 Years | Memorial Sloan Kettering Cancer Center | |
| Ex Vivo Expanded NK Cells Infusion Decrease Relapse Post Hematopoietic Stem Cell Transplantation | NCT05250362 | Hematologic Mal... | Allogeneic Hema... | 18 Years - 60 Years | Sichuan University | |
| Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma | NCT06207799 | Multiple Myelom... Post-transplant... Pre-transplant ... | Elranatamab Lenalidomide Plerixafor Melphalan Busulfan G-CSF Stem cell trans... | 18 Years - 75 Years | M.D. Anderson Cancer Center | |
| Autologous and Allogenic Transplantation With Campath-1H for T-Cell Lymphoma | NCT00505921 | Lymphoma | Campath-1H G-CSF GM-CSF BCNU Stem Cell Trans... Preparative Reg... Cytarabine Etoposide Melphalan Campath Fludarabine Cyclophosphamid... Low dose total ... | - 70 Years | M.D. Anderson Cancer Center | |
| Unrelated Donor Stem Cell Transplantation | NCT01364363 | Severe Aplastic... Paroxysmal Noct... Acute Myelogeno... Acute Lymphobla... Myelodysplastic... Myeloproliferat... Chronic Myeloge... Hodgkin's Lymph... Non-Hodgkin's L... Multiple Myelom... Chronic Lymphoc... Small Lymphocyt... Large Granulocy... | Allogeneic tran... | 18 Years - 69 Years | Scripps Health | |
| T-Regulatory Cell Kinetics, Stem Cell Transplantation, REGKINE | NCT00578461 | Leukemia Cancer Lymphoma Lymphoma, Hodgk... Lymphoma, Non-H... | Ara C Mesna Cyclophosphamid... TBI-Total Body ... | - 64 Years | Baylor College of Medicine | |
| Allogeneic Transplantation in Patients With Cutaneous T-Cell Lymphoma | NCT00506129 | Lymphoma Disorder Relate... | Fludarabine Melphalan Allogeneic Tran... Thymoglobulin | - 70 Years | M.D. Anderson Cancer Center | |
| Haploidentical Stem Cell Transplantation Using Post-Transplant Cyclophosphamide | NCT03088709 | Acute Myeloid L... Acute Lymphocyt... Myelodysplastic... Non-hodgkin Lym... Chronic Lymphoc... | Cyclophosphamid... Tacrolimus Mycophenolate m... Haploidentical ... | 16 Years - 90 Years | Loyola University | |
| Belinostat Combined With Azacitidine/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Refractory or Relapsed Lymphoma | NCT02701673 | Lymphoma | Busulfan Caphosol Glutamine Pyridoxine Belinostat Azacitidine Gemcitabine Melphalan Stem Cell Trans... | 15 Years - 65 Years | M.D. Anderson Cancer Center | |
| Allogeneic Transplantation in Patients With Cutaneous T-Cell Lymphoma | NCT00506129 | Lymphoma Disorder Relate... | Fludarabine Melphalan Allogeneic Tran... Thymoglobulin | - 70 Years | M.D. Anderson Cancer Center | |
| Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab in Autologous Stem Cell Transplantation | NCT00591630 | Diffuse Large C... Lymphoma | Zevalin Carmustine Etoposide Cytarabine Melphalan Rituximab Stem Cell Trans... | 18 Years - 70 Years | M.D. Anderson Cancer Center | |
| Anti-Leukemic Dendritic Cell Activated Donor Lymphocytes | NCT00048100 | Leukemia, Myelo... | Apheresis Stem Cell Trans... | 18 Years - 65 Years | M.D. Anderson Cancer Center | |
| Clofarabine-Melphalan-Alemtuzumab Conditioning in Patients With Advanced Hematologic Malignancies | NCT00943592 | Advanced Hemato... Leukemia Preleukemia | Clofarabine Melphalan Campath Stem Cell Trans... | 18 Years - 75 Years | University of Chicago | |
| Dose Augmented Rituximab and ICE for Pts With Primary Refractory and Poor Risk Relapsed Aggressive B-Cell NHL | NCT00588094 | Lymphoma B-cell Non-Hodg... | Rituximab, Ifos... | 18 Years - 72 Years | Memorial Sloan Kettering Cancer Center | |
| IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma Patients | NCT01009840 | Multiple Myelom... | IV busulfan bortezomib Autologous Hema... | 18 Years - 75 Years | Otsuka Pharmaceutical Development & Commercialization, Inc. | |
| Allogeneic Transplantation in Patients With Cutaneous T-Cell Lymphoma | NCT00506129 | Lymphoma Disorder Relate... | Fludarabine Melphalan Allogeneic Tran... Thymoglobulin | - 70 Years | M.D. Anderson Cancer Center | |
| Stem Cell Transplant and Zoledronic Acid Improve Outcome in Previously Untreated Patients With Multiple Myeloma | NCT01234129 | Multiple Myelom... | zoledronic acid | 18 Years - 65 Years | Instituto Mexicano del Seguro Social | |
| Nonmyeloablative Stem Cell Transplant in Elderly | NCT00382759 | Hematological M... | stem cell trans... | 60 Years - | Azienda Ospedaliera San Giovanni Battista | |
| Immune Reconstitution in Stem Cell Transplant Recipients | NCT02129543 | Cancer | Blood Draw | 18 Years - 75 Years | University of Miami | |
| Vaccination in the Peripheral Stem Cell Transplant Setting for Acute Myelogenous Leukemia | NCT00116467 | Acute Myelogeno... | GVAX leukemia v... | 18 Years - 60 Years | Cell Genesys | |
| Multivirus-specific T Cells in the Treatment of Refractory CMV and/or EBV Infection After Allo-HSCT | NCT06075927 | CMV Infection EBV Infection Stem Cell Trans... | Virus specific ... | 18 Years - 70 Years | Peking University People's Hospital | |
| Isatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma | NCT05346809 | Lymphoma Multiple Myelom... Non-Hodgkin Lym... Relapsed Hodgki... | Isatuximab Standard Proced... | 18 Years - | Columbia University | |
| Sm-EDTMP and Autologous Peripheral Blood Stem Cell Transplantation for Breast Cancer Patients With Bone Only Metastases | NCT00429507 | Breast Cancer Bone Metastases | 153 Sm-EDTMP Questionnaire Stem Cell Trans... | 18 Years - 65 Years | M.D. Anderson Cancer Center | |
| CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma | NCT01746173 | T-cell Non-Hodg... | Cyclophosphamid... Doxorubicin Vincristine Etoposide Prednisone Filgrastim Plerixafor Stem Cell Colle... Palifermin Gemcitabine Busulfan Melphalan Stem Cell Trans... | 18 Years - 70 Years | Dana-Farber Cancer Institute | |
| Remote Temperature Data for Early Detection of Febrile Neutropenia | NCT05180838 | Hematologic Mal... | BioSticker | 18 Years - 80 Years | University of Colorado, Denver | |
| Study of Iberdomide in People With Multiple Myeloma Who Have Had an Autologous Hematopoietic Stem Cell Transplant (AHCT) | NCT05354557 | Multiple Myelom... | Iberdomide | 18 Years - 75 Years | Memorial Sloan Kettering Cancer Center | |
| Safety of Post-transplant Alpha-beta Depleted T-cell Infusion Following Haploidentical Stem Cell Transplant (Haplo SCT) | NCT02193880 | Hematologic Neo... Graft-Versus-Ho... | Alpha-beta depl... | 19 Years - 65 Years | University of Alabama at Birmingham | |
| Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning | NCT01572662 | Leukemia Acute Myeloid L... Acute Lymphocyt... Chronic Myeloid... Chronic Lymphoc... Myeloproliferat... Non-Hodgkins Ly... Hodgkins Lympho... Multiple Myelom... Myelodysplastic... | Fludarabine mon... Busulfan Stem Cell Infus... Tacrolimus Methotrexate G-CSF | 5 Years - 75 Years | M.D. Anderson Cancer Center | |
| Purged Circulating Tumor Cells (CTCs) From Metastatic Breast Cancer | NCT00429182 | Breast Cancer Metastatic Brea... Invasive Breast... | Carboplatin Cyclophosphamid... Thiotepa Stem Cell Trans... | 18 Years - 55 Years | M.D. Anderson Cancer Center | |
| Autologous Transplantation for Chronic Myelogenous Leukemia | NCT01003054 | Chronic Myeloge... | Busulfan Cyclophosphamid... Imatinib Mesyla... Autologous Stem... | - 70 Years | M.D. Anderson Cancer Center | |
| A Controlled Study of Stem Cell Transplantation Medical Home Care Compared to Standard Hospital Care | NCT01725022 | Hematologic Mal... | Home Care | 18 Years - 80 Years | Duke University | |
| Intensive Chemo-Radiotherapy With Peripheral Blood Progenitor Cell Rescue for Children With Advanced Neuroblastoma and Sarcomas | NCT00165139 | Neuroblastoma Ewings Sarcoma Non-rhabdomyosa... | Vincristine Cyclophosphamid... Adriamycin Etoposide (VP-1... Cisplatin Carboplatin Melphalan Ifosfamide G-CSF (granuloc... Mesna | - 19 Years | Dana-Farber Cancer Institute | |
| Belinostat Combined With Azacitidine/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Refractory or Relapsed Lymphoma | NCT02701673 | Lymphoma | Busulfan Caphosol Glutamine Pyridoxine Belinostat Azacitidine Gemcitabine Melphalan Stem Cell Trans... | 15 Years - 65 Years | M.D. Anderson Cancer Center | |
| Nutrition and Metabolic Prehabilitation in HSCT Patients UK and ROI. BSBMT Multi-centre Survey. | NCT05352789 | Haematological ... Bone Marrow Tra... Stem Cell Trans... Nutrition Aspec... Nutritional and... Exercise Interv... Prehabilitation | Non validated S... | 18 Years - | Nottingham University Hospitals NHS Trust | |
| Nonmyeloablative Stem Cell Transplant in Elderly | NCT00382759 | Hematological M... | stem cell trans... | 60 Years - | Azienda Ospedaliera San Giovanni Battista | |
| Vaccination in the Peripheral Stem Cell Transplant Setting for Acute Myelogenous Leukemia | NCT00116467 | Acute Myelogeno... | GVAX leukemia v... | 18 Years - 60 Years | Cell Genesys | |
| Busulfan Plus Clofarabine Followed by Allogeneic Hematopoietic Stem Cell Transplantation | NCT00990249 | Leukemia Lymphoma Allogeneic Haem... Acute Lymphobla... | Busulfan Clofarabine Thymoglobulin Stem Cell Trans... | - 65 Years | M.D. Anderson Cancer Center | |
| Immune Reconstitution in Stem Cell Transplant Recipients | NCT02129543 | Cancer | Blood Draw | 18 Years - 75 Years | University of Miami | |
| Critical Care Outcomes of Hematologic Oncology Patients | NCT03449953 | Hematologic Mal... Stem Cell Trans... | 16 Years - | Mount Sinai Hospital, Canada | ||
| A Study Evaluating a Proprietary Amino Acid Mixture (Enterade®) in Patients Receiving High-Dose Melphalan Conditioning Followed by Autologous Stem Cell Transplantation for Multiple Myeloma and Non-Hodgkin Lymphoma | NCT02919670 | Multiple Myelom... Non-Hodgkin's L... | Enterade Placebo Standard Suppor... | 18 Years - | Dana-Farber Cancer Institute | |
| Intravenous (IV) AMD3100 for Mobilization and Matched Related Transplant for Advanced Hematological Malignancies | NCT00914849 | Hematologic Neo... | AMD3100 Leukopheresis Stem cell trans... | 18 Years - 65 Years | Washington University School of Medicine | |
| Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma | NCT02098109 | Multiple Myelom... Lymphoma, Non-H... | XM02 Filgrastim Filgrastim Apheresis Plerixafor Stem Cell Trans... | 18 Years - | Washington University School of Medicine | |
| Mini Allo Stem Cell Transplantation for the Treatment of Solid Tumors | NCT00997529 | Metastatic Soli... | nonmyeloablativ... | 18 Years - 60 Years | Beth Israel Deaconess Medical Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
